[go: up one dir, main page]

PE20110943A1 - Formulacion oral solida de alisquireno - Google Patents

Formulacion oral solida de alisquireno

Info

Publication number
PE20110943A1
PE20110943A1 PE2011001391A PE2011001391A PE20110943A1 PE 20110943 A1 PE20110943 A1 PE 20110943A1 PE 2011001391 A PE2011001391 A PE 2011001391A PE 2011001391 A PE2011001391 A PE 2011001391A PE 20110943 A1 PE20110943 A1 PE 20110943A1
Authority
PE
Peru
Prior art keywords
solid oral
alisquiren
oral formulation
tablet
amnera
Prior art date
Application number
PE2011001391A
Other languages
English (en)
Inventor
Sabine Desset-Brethes
Stefan Hirsch
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40770648&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20110943(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PE20110943A1 publication Critical patent/PE20110943A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

REFERIDA A UNA FORMA DE DOSIFICACION UNITARIA SOLIDA ORAL EN FORMA DE UNA TABLETA QUE COMPRENDE UN NUCLEO Y UN RECUBRIMIENTO EXTERNO A AMNERA DE UNA PELICULA, DONDE EL NUCLEO COMPRENDE ALISQUIRENO O UNA SAL FARMACEUTICAMNETE ACEPTABLE DEL MISMO Y EL RECUBRIMIENTO EXTERNO COMPRENDE UN COPOLIMERO DE METACRILATO DE AMONIO. DICHA TABLETA ES UTIL EN EL TRATAMIENTO DE DE HIPERTENSION, ANGINA, MIOPATIA CARDIACA DIABETICA, ENTRE OTRAS
PE2011001391A 2009-01-28 2010-01-27 Formulacion oral solida de alisquireno PE20110943A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP09151496 2009-01-28

Publications (1)

Publication Number Publication Date
PE20110943A1 true PE20110943A1 (es) 2012-01-22

Family

ID=40770648

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2011001391A PE20110943A1 (es) 2009-01-28 2010-01-27 Formulacion oral solida de alisquireno

Country Status (27)

Country Link
US (1) US20110287100A1 (es)
EP (1) EP2391345B1 (es)
JP (1) JP2012516299A (es)
KR (1) KR20110117199A (es)
CN (1) CN102300558A (es)
AR (1) AR075179A1 (es)
AU (1) AU2010209787B2 (es)
BR (1) BRPI1007452A2 (es)
CA (1) CA2749531A1 (es)
CL (1) CL2011001817A1 (es)
CO (1) CO6400184A2 (es)
EC (1) ECSP11011289A (es)
ES (1) ES2525648T3 (es)
IL (1) IL213918A0 (es)
MA (1) MA33060B1 (es)
MX (1) MX2011007779A (es)
MY (1) MY153852A (es)
NZ (1) NZ593622A (es)
PE (1) PE20110943A1 (es)
PL (1) PL2391345T3 (es)
PT (1) PT2391345E (es)
RU (1) RU2535090C2 (es)
SG (1) SG172226A1 (es)
TN (1) TN2011000307A1 (es)
TW (1) TWI468191B (es)
WO (1) WO2010086312A1 (es)
ZA (1) ZA201104489B (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5822758B2 (ja) * 2011-03-02 2015-11-24 第一三共ヘルスケア株式会社 速溶性防湿フィルムコーティング製剤及びその製造方法
EP2596802A1 (en) * 2011-11-23 2013-05-29 PLS-Design GmbH Pharmaceutical composition for treatment of allergic reactions
EP4609912A3 (en) * 2016-02-03 2025-11-12 Novartis AG New use of a combination of sacubitril and valsartan
US12171878B2 (en) 2018-08-10 2024-12-24 Kissei Pharmaceutical Co., Ltd. Sucroferric oxyhydroxide-containing granules and pharmaceutical composition
TW202045142A (zh) 2019-02-22 2020-12-16 英商康泰倫特英國斯文敦載迪斯有限公司 將儲存期間藥物顆粒塗覆材料的黏聚最小化以穩定化醫藥產品的崩解時間
SG11202108659XA (en) 2019-02-22 2021-09-29 Catalent Uk Swindon Zydis Ltd Minimizing aeration of suspensions during in-line mixing
CA3129404A1 (en) 2019-02-22 2020-08-27 Catalent U.K. Swindon Zydis Limited Preserving functionally-coated api particles produced by solventless mixing processes in aqueous suspension
WO2020169989A1 (en) 2019-02-22 2020-08-27 Catalent U.K. Swindon Zydis Limited Minimizing agglomeration, aeration, and preserving the coating of pharmaceutical compositions comprising ibuprofen
WO2021011538A1 (en) * 2019-07-15 2021-01-21 R.P. Scherer Technologies, Llc Capsule dosage forms, methods of preparation and methods of use thereof
WO2022024066A1 (en) 2020-07-31 2022-02-03 Catalent U.K. Swindon Zydis Limited Pharmaceutical compositions comprising coated api
EP4255495A4 (en) 2020-12-03 2025-10-08 Battelle Memorial Institute COMPOSITIONS OF POLYMERIC NANOPARTICLES AND DNA NANOSTRUCTURES AND METHODS FOR NON-VIRAL DELIVERY
WO2022216977A1 (en) 2021-04-07 2022-10-13 Batelle Memorial Institute Rapid design, build, test, and learn technologies for identifying and using non-viral carriers
WO2025072751A1 (en) 2023-09-29 2025-04-03 Battelle Memorial Institute Polymer nanoparticle compositions for in vivo expression of polypeptides
WO2025105451A1 (ja) * 2023-11-17 2025-05-22 第一三共ヘルスケア株式会社 固形製剤
US12441996B2 (en) 2023-12-08 2025-10-14 Battelle Memorial Institute Use of DNA origami nanostructures for molecular information based data storage systems

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY119161A (en) 1994-04-18 2005-04-30 Novartis Ag Delta-amino-gamma-hydroxy-omega-aryl-alkanoic acid amides with enzyme especially renin inhibiting activities
DE19842753A1 (de) * 1998-09-18 2000-03-23 Bayer Ag Agitationsunabhängige pharmazeutische Retardzubereitungen und Verfahren zu ihrer Herstellung
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
AR034813A1 (es) * 2001-07-20 2004-03-17 Novartis Ag Composiciones farmaceuticas y uso de las mismas
US20040266743A1 (en) * 2003-05-09 2004-12-30 Pharmacia Corporation Combination of an aldosterone receptor antagonist and a renin inhibitor
AR048431A1 (es) * 2004-03-17 2006-04-26 Novartis Ag Formulaciones galenicas de compuestos organicos
WO2005105054A1 (en) * 2004-04-15 2005-11-10 Dr. Reddy's Laboratories Ltd. Dosage form having polymorphic stability
EP1799199B1 (en) * 2004-10-08 2012-03-28 Novartis AG Use of renin inhibitors for the prevention or treatment of diastolic dysfunction or diastolic heart failure
BRPI0817275A2 (pt) * 2007-09-28 2015-06-16 Novartis Ag Combinação farmacêutica de alisquireno e valsartana

Also Published As

Publication number Publication date
AR075179A1 (es) 2011-03-16
TWI468191B (zh) 2015-01-11
SG172226A1 (en) 2011-07-28
MX2011007779A (es) 2011-08-12
PT2391345E (pt) 2014-12-03
EP2391345B1 (en) 2014-09-03
AU2010209787A1 (en) 2011-07-14
ZA201104489B (en) 2012-02-29
WO2010086312A1 (en) 2010-08-05
TN2011000307A1 (en) 2012-12-17
AU2010209787B2 (en) 2013-06-06
EP2391345A1 (en) 2011-12-07
RU2535090C2 (ru) 2014-12-10
ECSP11011289A (es) 2011-09-30
KR20110117199A (ko) 2011-10-26
CA2749531A1 (en) 2010-08-05
PL2391345T3 (pl) 2015-03-31
MY153852A (en) 2015-03-31
JP2012516299A (ja) 2012-07-19
CO6400184A2 (es) 2012-03-15
HK1161125A1 (en) 2012-08-24
NZ593622A (en) 2013-12-20
CL2011001817A1 (es) 2012-01-13
BRPI1007452A2 (pt) 2016-02-16
MA33060B1 (fr) 2012-02-01
US20110287100A1 (en) 2011-11-24
ES2525648T3 (es) 2014-12-26
TW201038300A (en) 2010-11-01
IL213918A0 (en) 2011-07-31
CN102300558A (zh) 2011-12-28
RU2011135417A (ru) 2013-03-10

Similar Documents

Publication Publication Date Title
PE20110943A1 (es) Formulacion oral solida de alisquireno
CL2011002858A1 (es) Uso de una composicion farmaceutica transmucosa oral que comprende dexmedetomidina y una sal farmaceuticamente aceptable y un excipiente farmaceuticamente aceptable para preparar un medicamento util para tratar o prevenir el dolor.
EA201690223A1 (ru) Ингибиторы фактора в комплемента на основе производных пиперидинилиндола и их применение
CO6382125A2 (es) Inhibidores de proteína quinasa
CL2012002356A1 (es) Compuestos heterociclicos acidos derivados de ariltriazolonas ligadas a bisarilo, inhibidores de receptores de vasopresina v1a y v2; procedimiento de preparacion; composicion farmaceutica; y su uso para tratar y/o prevenir insuficiencia cardiaca aguda y cronica, hiponatremia, entre otras.
EA201001577A1 (ru) Ингибитор дпп-4 в комбинации с дополнительным противодиабетическим агентом, таблетки, включающие указанные композиции, их применение и способ их получения
EA201100358A1 (ru) Дабигатран для чрескожной хирургической катетеризации сердца
PE20140255A1 (es) Tableta dispersable en forma oral
UA106636C2 (uk) Морфолінотіазоли як позитивні алостеричні модулятори альфа 7
CL2013001136A1 (es) Un agente inhibitorio de la fosfodiesterasa 7 (pde7) para ser usado en el tratamiento o la reduccion de la posibilidad de una adiccion; y composicion farmaceutica, forma de dosificacion unitaria y kit farmaceutico que incluyen al inhibidor de fosfodiesterasa 7 (pde7) y un agente terapeutico adicional.
GT201500053A (es) Composicion farmaceutica recubierta que contiene regorafenib
UA111599C2 (uk) Композиція каспофунгіну
EA201171497A1 (ru) Снижение флуктуаций опиоидов в крови
CY1122387T1 (el) Διπλης χρησης δισκια στοματικης φαρμακευτικης συνθεσης θειικων αλατων και μεθοδοι χρησης αυτων
CO6592109A2 (es) Nueva forma cristalina de un derivado de ciclopropilbenzamida
CO6430497A2 (es) Metodo o sistema que usa biomarcadores para el seguimiento de un tratamiento
MX2013001279A (es) Composicion farmaceutica con un inhibidor selectivo de la enzima fosfodiesterasa en forma de gel oral.
CL2016002318A1 (es) Composición farmacéutica en forma de solución que comprende un portador líquido que comprende agua y entre 20% y 95% de uno o mas alcoholes y citrato de sildenafil disuelto en dicho portador líquido a una concentración de entre 7 y 125 mg/ml; métodos para obtenerla; forma de dosificación oral; forma de dosificación bucal; kits.
UA109544C2 (uk) Фармацевтична композиція, що містить парацетамол, та спосіб її виготовлення
CL2011000614A1 (es) Forma de dosificacion oral solida que comprende alisquireno solo o en combinacion con otro agente activo; proceso de preparacion; y uso en el tratamiento de enfermedades tales comohipertension, angina, ateroesclerosis, entre otras.
GEP201706743B (en) Oral formulation for the treatment of cardiovascular diseases
EA201200319A1 (ru) Введение активированного угля при оказании неотложной помощи в случае передозировки этексилата дабигатрана
PE20110293A1 (es) Combinacion de dosis fija en la forma de una tableta de una sola capa que comprende alisquireno y amlodipina
CL2015001940A1 (es) Formulación que comprende un compuesto de benzotiazolona.
CR20120617A (es) Combinación de inhibidores de xantna oxidasa y antagonistas del receptor de angiotensina ii y su uso

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed